display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - colorectal cancer (mCRC)
metastatic/advanced - colorectal cancer (mCRC)mCRC - 1st line (L1)mCRC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMblaze-370 ...
atezolizumab plus bevacizumab BACCI BACCI
atezolizumab plus cometinib Modul Cohort 4 IMblaze-370 ...
atezolizumab plus FOLFOXIRI plus bevacizumab AtezoTRIBE
atezolizumab plus SoC Modul Cohort 2
avelumab based treatment
avelumab alone SAMCO-PRODIGE 54
durvalumab based treatment Columbia 1
nivolumab based treatment
nivolumab plus SoC CheckMate 9X8 METIMMOX
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-177
Immune checkpoint association
durvalumab plus tremelimumab CO.26 study
nivolumab plus ipilimumab CheckMate 8HW

Study type: